Investigating how cannabidiol affects driving performance in healthy adults
Official title: The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex
Run by West Virginia University · NCT06686914 · Data updated 2026-11-12
This study is testing how different doses of CBD oil affect driving performance and alertness in healthy adults aged 18-30.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 30 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | West Virginia University Academic / other |
| Locations | 1 site (Morgantown, West Virginia) |
| Status | Recruiting |
| Started | June 30, 2025 |
| Main results expected | December 31, 2028 |
| Study ends | May 1, 2029 |
| Registry record updated | October 6, 2026 |
| Trial ID | NCT06686914 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy adults aged 18-30 who possess a current driver's license and have driven a vehicle in the past month.
✕Probably not a fit
Patients with serious chronic diseases or those currently using CBD or tobacco products may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to explore the effects of non-prescription cannabidiol (CBD) on driving performance, drowsiness, sedation, and cognitive function among healthy adults aged 18-30. Utilizing a randomized controlled trial design, the research will assess the impact of different doses of CBD oil (300mg and 150mg) compared to a placebo. The study will also analyze how these effects may vary by sex, ensuring a comprehensive understanding of CBD's influence on driving abilities. Participants must meet specific eligibility criteria, including a valid driver's license and a clean drug test.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the safety of CBD use for individuals who drive.
How similar studies have gone: While there is ongoing research into the effects of CBD, this specific investigation into driving performance is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Possess a current drivers' license * Driven a motor vehicle at least once in the past 30 days * Able to read English * Test negative for all substances on a urine drug test and complete a test drive to ensure the absence of simulation sickness * Not taking any daily prescription medications (excluding birth control) * Not diagnosed with any serious chronic disease by a licensed healthcare provider (including but not limited to Alzheimer's and related dementias, Parkinson's disease or other neurodegenerative disorder, major depressive or anxiety disorder, schizophrenia or other serious mental illness, arrhythmias, cataracts, glaucoma, chronic obstructive pulmonary disease, diabetes, epilepsy, sleep apnea, and fibromyalgia) * Have an individual willing to drive them home after testing or be taken home by study staff after testing Exclusion Criteria: * Currently smoke, vape or use tobacco products, used CBD in the past 30 days * Used illegal drugs in the past 30 days (e.g., cocaine/crack, heroin, methamphetamine, 3,4-methylenedioxy-methamphetamine, inhalants, phencyclidine, lysergic acid diethylamide, psilocybin mushrooms, or marijuana) * Are pregnant or lactating at time of study
Where it's running
-
West Virginia University
Morgantown, West Virginia, United States Recruiting
Study contacts
- Principal investigator: Toni M Rudisill, PhD — West Virginia University
- Study coordinator: Toni M Rudisill, PhD
- Email: trudisill@hsc.wvu.edu
- Phone: 3042930687
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ENLIGHT: Adding fundal mucosal ablation to endoscopic sleeve gastrostomy for obesity
This trial tests whether adding fundal mucosal ablation to endoscopic sleeve gastroplasty helps adults with obesity lose more weight and improve metabolic health compared with ESG alone.
-
EUS-Guided Ablation for Pancreatic and GI Lesions Registry
This registry collects real-world data on adults undergoing EUS-guided RFA or MWA to treat pancreatic or other GI lesions during routine care to see how these treatments affect lesion size, survival, and symptoms.
-
5% 5‑fluorouracil with or without 15% aluminum chloride for actinic keratoses
This will see if adding 15% aluminum chloride to 5% 5‑fluorouracil cream helps clear actinic keratoses on the scalp or forearms in adults with 4–15 lesions after one week of treatment.
-
Rapid HIV, HCV, and syphilis screening at a rural street-medicine clinic
A rapid fingerstick test is being tested in a mobile street-medicine clinic to see if it increases uptake and quick linkage to care for HIV, HCV, and syphilis among adults served by WVU Street Medicine.
-
Subcutaneous blinatumomab treatment for adults with CD19-positive mixed phenotype acute leukemia
This trial tests whether giving blinatumomab under the skin can help adults with CD19-positive mixed phenotype acute leukemia, including older or unfit newly diagnosed patients, those with measurable residual disease after remission, and those with relapsed or refractory disease.
-
Lifting More Than Weights: a resistance exercise program to reduce fatigue after breast cancer across socioeconomic groups
This project will try a tailored resistance exercise program to see if it helps reduce fatigue and improve readiness to exercise in Appalachian breast cancer survivors from different socioeconomic backgrounds.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.